Navigation Links
Advaxis, Inc Initiation Coverage Review Issued By Scimitar Equity, LLC
Date:7/15/2008

BOSTON, July 15 /PRNewswire/ --Scimitar Equity, LLC issues a review of Advaxis, Inc (OTC Bulletin Board: ADXS), entitled, "The New Generation of Cancer Immunotherapeutics".

This review is available at website: http://www.scimitarequity.com.

Based in North Brunswick, New Jersey, Advaxis, Inc is developing proprietary Listeria monocytogenes ("Lm") cancer vaccines based on technology developed by Dr. Yvonne Paterson, Professor of Microbiology at the University of Pennsylvania and Chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms to fight cancer safely. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets HPV-associated cancers such as cervical and head and neck. Current Lm vaccines in development target prostate, breast, ovarian and other cancers. Recently, Advaxis completed a Phase I clinical trial of Lovaxin C. A Phase II clinical trial is planned for patients with cervical intraepithelial neoplasia ("CIN"). The Lm platform also has applications in the fields of infectious disease and autoimmune disorders. For further information, please visit: http://www.advaxis.com .

Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about Advaxis, Inc (OTCBB: ADXS) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that
'/>"/>

SOURCE Scimitar Equity, LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
4. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
5. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
8. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
9. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2008)...gium and GENEVA, Sept. 3 /- Artelis S...n CHO based monoclonal antibody,production with th...rams,per liter. This record level was accomplished...1) a high-performance stable Selexis CHO,productio...scientists at,Selexis SA using their proprietary S...
(Date:9/3/2008)...howed that Multaq(R) (dronedarone) decreased the r...lation or atrial flutter already adeq...ATER, N.J., Sept. 3 /- The ...e ATHENA study were presented today at,the clinica...Cardiology,congress 2008, in Munich, Germany. Prev...
(Date:9/3/2008)...es Operations, Updates Zingo Launch Progress and A... Conference Call Today at 11:30 a...swire-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV )...,operations to focus on commercial and late-stage ...o a specialty pharmaceutical pain management,compa...
(Date:9/3/2008)... Evaluated in Repeat-Dosing Study in Subjects with...Call/ -- Sangamo,BioSciences, Inc. (Nasdaq: SGMO ...nical trial (SB-509-801) to evaluate its drug, SB-...tive motor-neuron disease for which there,are limi...g, SB-509, is an injectable formulation of a plasm...
Breaking Medicine Technology:Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5How schizophrenia develops 3A Major clues discovered 841 1How schizophrenia develops 3A Major clues discovered 841 2The Childrens Institute Launches The Campaign for an Amazing Future 3862 1The Childrens Institute Launches The Campaign for an Amazing Future 3862 2The Childrens Institute Launches The Campaign for an Amazing Future 3862 3Edwards Lifesciences Announces Schedule of Activities at TCT 2007 3858 1Edwards Lifesciences Announces Schedule of Activities at TCT 2007 3858 2Edwards Lifesciences Announces Schedule of Activities at TCT 2007 3858 3Edwards Lifesciences Announces Schedule of Activities at TCT 2007 3858 4Ohio Delegation Members Urge Colleagues to Vote for Override of SCHIP Veto 3854 1Ohio Delegation Members Urge Colleagues to Vote for Override of SCHIP Veto 3854 2
...wswire/ -- Portola,Pharmaceuticals, Inc. announced...54021, an oral Factor Xa inhibitor, today at the X...osis and Haemostasis,(ISTH) in Geneva, Switzerland... effective, and well tolerated for the,prevention ...undergoing total knee replacement (TKR) surgery. P...
...or for U.S. Trial -, MISSISSAUGA, ON, July 11, 200...n oncology company that identifies, develops,and c... worldwide,today announced results of secondary e...ebo-controlled, multi-center Phase IIb,trial (DLXL...,inhaled-delivery composition of free and liposome...
Other Medicine Technology:Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 2Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 3Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 4YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 2YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 3YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 4YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial 5
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
... first full-fledged Trauma center in India, Jai Pr...as conceived 22 years before, in 1984, is now read... All India Institute of Medical Sciences - JPNATC ...n-storey hospital with 200 beds, including 16 ICU ...
...y conducted a new study about alcoholism and publi...sm: Clinical & Experimental Research.// The study...ople initially fall asleep, but leads to poor-qual... night. · Escalated consumption of alcohol to aid...
...t rice (RYR) is known to contain several ingredien...tatin, and several trials have confirmed// its pos...onducted to assess the effectiveness and safety of...ipid levels in people with primary hyperlipidemia....
... study, using mice and heart muscle cells from rab...G?ttingen, Germany, have provided// a potential mo...beats known as ventricular tachyarrhythmias (VTs) ...iated with heart failure. Individuals who inherit...
Other Medicine News:Health News:Alcohol Dependence For Sleep Perceptions May Result In Alcoholism 2Health News:Alcohol Dependence For Sleep Perceptions May Result In Alcoholism 3
...orporate a layered design unique in the industry. ...ent stray electrosurgical burns along the shaft of...pacitive coupling; a well-documented patient safet...nstruments provides a neutral return path for capa...
...orporate a layered design unique in the industry. ...ent stray electrosurgical burns along the shaft of...pacitive coupling; a well-documented patient safet...nstruments provides a neutral return path for capa...
...orporate a layered design unique in the industry. ...ent stray electrosurgical burns along the shaft of...pacitive coupling; a well-documented patient safet...nstruments provides a neutral return path for capa...
The Auto Suture™ ExtraHand™ balloon retractor is designed to be used during open surgery, gasless endoscopy, as well as endoscopy with gas insufflation.
Medicine Products: